JP2019116474A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019116474A5 JP2019116474A5 JP2019012878A JP2019012878A JP2019116474A5 JP 2019116474 A5 JP2019116474 A5 JP 2019116474A5 JP 2019012878 A JP2019012878 A JP 2019012878A JP 2019012878 A JP2019012878 A JP 2019012878A JP 2019116474 A5 JP2019116474 A5 JP 2019116474A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- cancer
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022063412A JP2022088649A (ja) | 2010-03-26 | 2022-04-06 | Ｍｕｃ１６に対する抗体およびその使用方法 |
| JP2024043445A JP2024073610A (ja) | 2010-03-26 | 2024-03-19 | Ｍｕｃ１６に対する抗体およびその使用方法 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31796410P | 2010-03-26 | 2010-03-26 | |
| US61/317,964 | 2010-03-26 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018061671A Division JP2018117634A (ja) | 2010-03-26 | 2018-03-28 | Ｍｕｃ１６に対する抗体およびその使用方法 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019232781A Division JP2020072681A (ja) | 2010-03-26 | 2019-12-24 | Ｍｕｃ１６に対する抗体およびその使用方法 |
| JP2022063412A Division JP2022088649A (ja) | 2010-03-26 | 2022-04-06 | Ｍｕｃ１６に対する抗体およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019116474A JP2019116474A (ja) | 2019-07-18 |
| JP2019116474A5 true JP2019116474A5 (enExample) | 2020-02-13 |
| JP7100595B2 JP7100595B2 (ja) | 2022-07-13 |
Family
ID=44673895
Family Applications (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013501520A Active JP5837567B2 (ja) | 2010-03-26 | 2011-03-25 | Ｍｕｃ１６に対する抗体およびその使用方法 |
| JP2014210674A Active JP6463068B2 (ja) | 2010-03-26 | 2014-10-15 | Ｍｕｃ１６に対する抗体およびその使用方法 |
| JP2016080611A Pending JP2016144468A (ja) | 2010-03-26 | 2016-04-13 | Ｍｕｃ１６に対する抗体およびその使用方法 |
| JP2018061671A Withdrawn JP2018117634A (ja) | 2010-03-26 | 2018-03-28 | Ｍｕｃ１６に対する抗体およびその使用方法 |
| JP2019012878A Active JP7100595B2 (ja) | 2010-03-26 | 2019-01-29 | Ｍｕｃ１６に対する抗体およびその使用方法 |
| JP2019232781A Pending JP2020072681A (ja) | 2010-03-26 | 2019-12-24 | Ｍｕｃ１６に対する抗体およびその使用方法 |
| JP2022063412A Pending JP2022088649A (ja) | 2010-03-26 | 2022-04-06 | Ｍｕｃ１６に対する抗体およびその使用方法 |
| JP2024043445A Pending JP2024073610A (ja) | 2010-03-26 | 2024-03-19 | Ｍｕｃ１６に対する抗体およびその使用方法 |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013501520A Active JP5837567B2 (ja) | 2010-03-26 | 2011-03-25 | Ｍｕｃ１６に対する抗体およびその使用方法 |
| JP2014210674A Active JP6463068B2 (ja) | 2010-03-26 | 2014-10-15 | Ｍｕｃ１６に対する抗体およびその使用方法 |
| JP2016080611A Pending JP2016144468A (ja) | 2010-03-26 | 2016-04-13 | Ｍｕｃ１６に対する抗体およびその使用方法 |
| JP2018061671A Withdrawn JP2018117634A (ja) | 2010-03-26 | 2018-03-28 | Ｍｕｃ１６に対する抗体およびその使用方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019232781A Pending JP2020072681A (ja) | 2010-03-26 | 2019-12-24 | Ｍｕｃ１６に対する抗体およびその使用方法 |
| JP2022063412A Pending JP2022088649A (ja) | 2010-03-26 | 2022-04-06 | Ｍｕｃ１６に対する抗体およびその使用方法 |
| JP2024043445A Pending JP2024073610A (ja) | 2010-03-26 | 2024-03-19 | Ｍｕｃ１６に対する抗体およびその使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US9169328B2 (enExample) |
| EP (2) | EP3222632A1 (enExample) |
| JP (8) | JP5837567B2 (enExample) |
| AU (1) | AU2011230590C1 (enExample) |
| CA (4) | CA2793753C (enExample) |
| DK (1) | DK2552959T3 (enExample) |
| ES (1) | ES2621874T3 (enExample) |
| HK (1) | HK1244496A1 (enExample) |
| HU (1) | HUE032519T2 (enExample) |
| ME (1) | ME02670B (enExample) |
| PL (1) | PL2552959T3 (enExample) |
| PT (1) | PT2552959T (enExample) |
| WO (1) | WO2011119979A2 (enExample) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2793753C (en) | 2010-03-26 | 2018-06-05 | Memorial Sloan-Kettering Cancer Center | Antibodies to muc16 and methods of use thereof |
| US9402916B2 (en) | 2011-03-17 | 2016-08-02 | The University Of Birmingham | Re-directed immunotherapy |
| EP2961831B1 (en) | 2013-02-26 | 2020-06-10 | Memorial Sloan Kettering Cancer Center | Compositions and methods for immunotherapy |
| AU2014243836B2 (en) * | 2013-03-13 | 2017-12-07 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating cancer |
| KR20230004939A (ko) * | 2014-02-07 | 2023-01-06 | 맥마스터 유니버시티 | 3기능성 t 세포-항원 커플러 및 이의 제조 방법 및 용도 |
| KR20170041167A (ko) * | 2014-02-19 | 2017-04-14 | 조디 베리 | 마르부르크 단클론성 항체 |
| EP3209690B1 (en) | 2014-10-20 | 2021-05-05 | Juno Therapeutics, Inc. | Methods and compositions for dosing in adoptive cell therapy |
| WO2016089916A1 (en) * | 2014-12-02 | 2016-06-09 | Roger Williams Hospital | Methods and compositons for treating cancer |
| EP4190817A1 (en) | 2015-03-17 | 2023-06-07 | Memorial Sloan Kettering Cancer Center | Anti-muc16 antibodies and uses thereof |
| CA2981304C (en) * | 2015-04-02 | 2024-01-02 | Memorial Sloan Kettering Cancer Center | Tnfrsf14/hvem proteins and methods of use thereof |
| MX2017014822A (es) | 2015-05-18 | 2018-04-30 | Tcr2 Therapeutics Inc | Composiciones y métodos para la reprogramación del tcr con proteínas de fusión. |
| GB201511546D0 (en) | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| HRP20202019T1 (hr) | 2015-07-01 | 2021-04-30 | Immatics Biotechnologies Gmbh | Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv raka jajnika i drugih malignih tumora |
| WO2017065203A1 (ja) * | 2015-10-14 | 2017-04-20 | 日本全薬工業株式会社 | イヌアトピー性皮膚炎の治療及び診断のために用いる抗イヌｔａｒｃ抗体 |
| WO2017070608A1 (en) | 2015-10-23 | 2017-04-27 | Eureka Therapeutics, Inc. | Antibody/t-cell receptor chimeric constructs and uses thereof |
| CA3032498A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| HRP20221202T1 (hr) * | 2016-09-23 | 2022-12-09 | Regeneron Pharmaceuticals, Inc. | Anti-muc16 (mucin 16) antitijela |
| MX2019003899A (es) | 2016-10-07 | 2019-08-14 | Tcr2 Therapeutics Inc | Composiciones y metodos para reprogramacion de receptores de linfocitos t mediante el uso de proteinas de fusion. |
| EP3544996A2 (en) | 2016-11-22 | 2019-10-02 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| WO2018102795A2 (en) | 2016-12-02 | 2018-06-07 | University Of Southern California | Synthetic immune receptors and methods of use thereof |
| MX2019010804A (es) | 2017-03-15 | 2020-01-23 | Silverback Therapeutics Inc | Compuestos de benzazepina, conjugados y usos de los mismos. |
| JP2020517259A (ja) | 2017-04-19 | 2020-06-18 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 操作された抗原受容体を発現する免疫細胞 |
| CN110741016A (zh) | 2017-04-26 | 2020-01-31 | 优瑞科生物技术公司 | 嵌合抗体/t-细胞受体构筑体及其用途 |
| CN107557336B (zh) * | 2017-09-15 | 2020-02-14 | 山东兴瑞生物科技有限公司 | 一种抗muc16安全型嵌合抗原受体修饰的免疫细胞及其应用 |
| JP7227630B2 (ja) | 2017-10-12 | 2023-02-22 | マックマスター ユニバーシティー | Ｙ１８２ｔ突然変異を有するｔ細胞－抗原カプラおよびその方法ならびに使用 |
| JP7273421B2 (ja) | 2018-02-21 | 2023-05-15 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用 |
| RU2747095C2 (ru) * | 2018-05-11 | 2021-04-26 | Федеральное государственное бюджетное учреждение "Российский научный центр рентгенорадиологии" Министерства здравоохранения российской федерации (ФГБУ "РНЦРР" Минздрава России) | Мономолекулярный химерный т-клеточный рецептор к раковому антигену са125 |
| EP3802615A4 (en) * | 2018-06-04 | 2022-04-13 | Precigen, Inc. | Muc16 specific chimeric antigen receptors and uses thereof |
| US11110123B2 (en) | 2018-07-17 | 2021-09-07 | Triumvira Immunologics Usa, Inc. | T cell-antigen coupler with various construct optimizations |
| US10640562B2 (en) | 2018-07-17 | 2020-05-05 | Mcmaster University | T cell-antigen coupler with various construct optimizations |
| SG11202100838QA (en) * | 2018-07-26 | 2021-02-25 | Tcr2 Therapeutics Inc | Compositions and methods for tcr reprogramming using target specific fusion proteins |
| SG11202101980VA (en) | 2018-09-12 | 2021-03-30 | Silverback Therapeutics Inc | Methods and composition for the treatment of disease with immune stimulatory conjugates |
| US20220048895A1 (en) | 2018-09-12 | 2022-02-17 | Silverback Therapeutics, Inc. | Substituted benzazepine compounds, conjugates, and uses thereof |
| WO2020056194A1 (en) | 2018-09-12 | 2020-03-19 | Silverback Therapeutics, Inc. | Benzazepine compounds, conjugates, and uses thereof |
| AU2019337652A1 (en) | 2018-09-12 | 2021-03-18 | Silverback Therapeutics, Inc. | Antibody conjugates of toll-like receptor agonists |
| TW202031679A (zh) * | 2018-10-26 | 2020-09-01 | 日商橘生藥品工業股份有限公司 | 高效率之基因改造細胞之製作方法 |
| EP4640698A3 (en) * | 2018-11-16 | 2026-02-25 | Memorial Sloan Kettering Cancer Center | Antibodies to mucin-16 and methods of use thereof |
| CA3120800A1 (en) | 2018-12-17 | 2020-06-25 | Revitope Limited | Twin immune cell engager |
| JP7675016B2 (ja) * | 2019-05-08 | 2025-05-12 | メモリアル スローン ケタリング キャンサー センター | ムチン－１６に対するヒト化抗体およびそれを使用する方法 |
| WO2021019706A1 (ja) * | 2019-07-31 | 2021-02-04 | 国立大学法人信州大学 | Ｃａｒ発現免疫細胞を含む細胞集団の製造方法 |
| BR112022002720A2 (pt) | 2019-08-15 | 2022-10-11 | Silverback Therapeutics Inc | Formulações de conjugados de benzazepinas e usos das mesmas |
| CA3151322A1 (en) | 2019-10-01 | 2021-04-08 | Silverback Therapeutics, Inc. | Combination therapy with immune stimulatory conjugates |
| EP4106819A1 (en) | 2020-02-21 | 2022-12-28 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
| IL299508A (en) | 2020-07-01 | 2023-02-01 | Ars Pharmaceuticals Inc | Anti-asgr1 antibody conjugates and uses thereof |
| CA3188656A1 (en) | 2020-07-17 | 2022-01-20 | Simurx, Inc. | Chimeric myd88 receptors for redirecting immunosuppressive signaling and related compositions and methods |
| CN116635064A (zh) | 2020-12-18 | 2023-08-22 | 世纪治疗股份有限公司 | 具有适应性受体特异性的嵌合抗原受体系统 |
| WO2022140388A1 (en) | 2020-12-21 | 2022-06-30 | Allogene Therapeutics, Inc. | Protease-activating cd45-gate car |
| EP4284918A1 (en) | 2021-01-29 | 2023-12-06 | Allogene Therapeutics, Inc. | Knockdown or knockout of one or more of tap2, nlrc5, beta2m, trac, rfx5, rfxap and rfxank to mitigate t cell recognition of allogeneic cell products |
| KR20240037892A (ko) | 2021-06-01 | 2024-03-22 | 트리움비라 이뮤놀로직스 유에스에이, 인크. | 클라우딘 18.2 t 세포-항원 커플러 및 이의 용도 |
| CN119654406A (zh) | 2022-07-29 | 2025-03-18 | 艾洛基治疗公司 | 具有降低的基因表达以减轻免疫细胞识别的经工程化的细胞 |
| WO2025036848A1 (en) | 2023-08-11 | 2025-02-20 | Wuxi Biologics (Shanghai) Co., Ltd. | Anti-muc16 antibodies and uses thereof |
| CN117024596B (zh) * | 2023-08-18 | 2024-02-27 | 镜像绮点(上海)细胞技术有限公司 | 肿瘤原代细胞特异性标记与活体成像 |
| WO2025096560A1 (en) | 2023-10-30 | 2025-05-08 | Allogene Therapeutics, Inc. | Engineered cells |
| CN119978126A (zh) * | 2023-11-10 | 2025-05-13 | 深圳市菲鹏生物治疗股份有限公司 | 抗muc16抗体、靶向muc16的嵌合抗原受体及其应用 |
| WO2025104253A1 (en) * | 2023-11-17 | 2025-05-22 | Wuxi Biologics (Shanghai) Co., Ltd. | Anti-muc16 antibodies and uses thereof |
| WO2025168802A1 (en) | 2024-02-09 | 2025-08-14 | Oslo Universitetssykehus Hf | Chimeric antigen receptor binding to ca125 for treating ovarian cancer |
| CN119638843B (zh) * | 2024-03-20 | 2025-08-26 | 武汉勖瑞生物科技有限责任公司 | 一种抗ca125蛋白的单克隆抗体及其应用 |
| CN118791617B (zh) * | 2024-07-02 | 2025-03-07 | 安徽德合功生物科技有限公司 | Ca125单克隆抗体及其应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US505713A (en) | 1893-09-26 | Thomas j | ||
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4978745A (en) | 1987-11-23 | 1990-12-18 | Centocor, Inc. | Immunoreactive heterochain antibodies |
| US4975369A (en) | 1988-04-21 | 1990-12-04 | Eli Lilly And Company | Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen |
| AU5554190A (en) | 1989-05-08 | 1990-11-29 | Mark I. Farber | Process and apparatus for the recovery of precious metals from slag, tailings and other materials |
| ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| US5976818A (en) | 1991-12-16 | 1999-11-02 | The Board Of Trustees Of The University Of Arkansas | Monoclonal antibodies which identify the glycoprotein carrying the CA 125 epitope |
| DK0563475T3 (da) | 1992-03-25 | 2000-09-18 | Immunogen Inc | Konjugater af cellebindende midler og derivater af CC-1065 |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| WO1995021381A1 (en) | 1994-02-01 | 1995-08-10 | The Rockefeller University | Methods and agents for measuring and controlling multidrug resistance |
| US6107090A (en) | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
| SI0970126T1 (en) | 1997-04-14 | 2001-08-31 | Micromet Ag | Novel method for the production of antihuman antigen receptors and uses thereof |
| US20030148463A1 (en) | 1997-04-14 | 2003-08-07 | Micromet Ag | Novel method for the production of anti-human antigen receptors and uses thereof |
| CU22731A1 (es) | 1998-02-05 | 2002-02-28 | Centro Inmunologia Molecular | Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen |
| US20020119158A1 (en) | 1998-12-17 | 2002-08-29 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
| WO2000077246A2 (en) | 1999-06-14 | 2000-12-21 | Novo Nordisk A/S | A METHOD FOR IDENTIFYING A DRUG CANDIDATE HAVING AN INHIBITORY ACTION ON FVII-TF ACTIVITY, AND FVIIa/TF ACTIVITY INHIBITING COMPOUNDS |
| US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| NZ517772A (en) | 1999-11-24 | 2004-03-26 | Immunogen Inc | Cytotoxic agents comprising taxanes and their therapeutic use |
| US6632979B2 (en) | 2000-03-16 | 2003-10-14 | Genentech, Inc. | Rodent HER2 tumor model |
| US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
| ITRM20010408A1 (it) | 2001-07-10 | 2003-01-10 | Univ Napoli Federico Ii | Mini-anticorpo umano citotossico per cellule tumorali che esprimono il recettore erbb2. |
| EP1536814A4 (en) | 2002-07-03 | 2006-02-15 | Immunogen Inc | ANTIQUE RPER AGAINST NON-SHED-MUC1 AND MUC16, AND ITS USES |
| US6905839B2 (en) | 2002-07-31 | 2005-06-14 | Takashi Furuta | In vivo phenotyping for human cytochrome P450 3A activity |
| GB2395270B (en) * | 2002-11-14 | 2006-08-16 | Univ Nottingham | Tumour marker proteins and uses thereof |
| ATE472338T1 (de) | 2003-02-20 | 2010-07-15 | Seattle Genetics Inc | Anti-cd70 antikörper-arzneimittelkonjugate und ihre verwendung zur behandlung von krebs |
| CA2559809A1 (en) | 2004-03-12 | 2005-11-10 | Human Genome Sciences, Inc. | Antibodies against human g-protein chemokine receptor (ccr5) hdgnr10 |
| CN1981054A (zh) | 2004-05-14 | 2007-06-13 | 加利福尼亚大学董事会 | 用抗wnt2单克隆抗体和sirna治疗癌症的方法 |
| KR101270829B1 (ko) | 2004-09-23 | 2013-06-07 | 제넨테크, 인크. | 시스테인 유전자조작 항체 및 접합체 |
| NZ563370A (en) * | 2005-06-20 | 2010-10-29 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor |
| AR066476A1 (es) * | 2007-05-08 | 2009-08-19 | Genentech Inc | Anticuerpos anti-muc16 disenados con cisteina y conjugaods de anticuerpos y farmacos |
| CA2793753C (en) | 2010-03-26 | 2018-06-05 | Memorial Sloan-Kettering Cancer Center | Antibodies to muc16 and methods of use thereof |
| US9002545B2 (en) | 2011-01-07 | 2015-04-07 | Wabtec Holding Corp. | Data improvement system and method |
| CN105358985B (zh) | 2013-07-09 | 2018-08-28 | 内布拉斯加大学董事会 | 靶向糖蛋白以治疗癌症的新方法 |
| EP4190817A1 (en) | 2015-03-17 | 2023-06-07 | Memorial Sloan Kettering Cancer Center | Anti-muc16 antibodies and uses thereof |
-
2011
- 2011-03-25 CA CA2793753A patent/CA2793753C/en active Active
- 2011-03-25 CA CA3188287A patent/CA3188287C/en active Active
- 2011-03-25 EP EP17150631.4A patent/EP3222632A1/en active Pending
- 2011-03-25 HU HUE11760326A patent/HUE032519T2/en unknown
- 2011-03-25 CA CA3255551A patent/CA3255551A1/en active Pending
- 2011-03-25 CA CA3002192A patent/CA3002192C/en active Active
- 2011-03-25 PL PL11760326T patent/PL2552959T3/pl unknown
- 2011-03-25 DK DK11760326.6T patent/DK2552959T3/en active
- 2011-03-25 WO PCT/US2011/030025 patent/WO2011119979A2/en not_active Ceased
- 2011-03-25 ME MEP-2017-89A patent/ME02670B/me unknown
- 2011-03-25 ES ES11760326T patent/ES2621874T3/es active Active
- 2011-03-25 PT PT117603266T patent/PT2552959T/pt unknown
- 2011-03-25 JP JP2013501520A patent/JP5837567B2/ja active Active
- 2011-03-25 US US13/635,090 patent/US9169328B2/en active Active
- 2011-03-25 AU AU2011230590A patent/AU2011230590C1/en active Active
- 2011-03-25 EP EP11760326.6A patent/EP2552959B1/en active Active
-
2014
- 2014-10-15 JP JP2014210674A patent/JP6463068B2/ja active Active
-
2015
- 2015-09-10 US US14/850,675 patent/US9790283B2/en active Active
-
2016
- 2016-04-13 JP JP2016080611A patent/JP2016144468A/ja active Pending
-
2017
- 2017-09-05 US US15/695,311 patent/US10759869B2/en active Active
-
2018
- 2018-03-23 HK HK18104038.6A patent/HK1244496A1/en unknown
- 2018-03-28 JP JP2018061671A patent/JP2018117634A/ja not_active Withdrawn
-
2019
- 2019-01-29 JP JP2019012878A patent/JP7100595B2/ja active Active
- 2019-12-24 JP JP2019232781A patent/JP2020072681A/ja active Pending
-
2020
- 2020-07-28 US US16/941,348 patent/US11834513B2/en active Active
-
2022
- 2022-04-06 JP JP2022063412A patent/JP2022088649A/ja active Pending
-
2024
- 2024-03-19 JP JP2024043445A patent/JP2024073610A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019116474A5 (enExample) | ||
| JP7562528B2 (ja) | 抗体及びその用途 | |
| JP7150880B2 (ja) | 抗－ｂ７－ｈ３抗体およびその用途 | |
| JP7461950B2 (ja) | Ｃｄ３抗体およびその医薬用途 | |
| CN107840887B (zh) | 一种新的pd-1单克隆抗体 | |
| JP2019519492A5 (enExample) | ||
| JP2020510422A5 (enExample) | ||
| CN112154157A (zh) | 抗ror1抗体及其用途 | |
| JP2021503455A5 (enExample) | ||
| JP2018522888A5 (enExample) | ||
| US20240301085A1 (en) | Humanized gpc3 antibody and application thereof | |
| KR20160127825A (ko) | 항-mcam 항체 및 관련된 사용 방법 | |
| IL302278A (en) | Combination treatment | |
| JP2024001073A5 (enExample) | ||
| US20240117035A1 (en) | Cldn18.2/cd3 bispecific antibodies for the therapy of cldn18.2-expressing solid tumors | |
| RU2018102803A (ru) | Мультивалентные и мультиспецифические гибридные белки, связывающиеся с dr5 | |
| CN114641504A (zh) | 抗b7h4抗体及其双抗和应用 | |
| CN119213023A (zh) | Ilt3和cd3结合剂以及其使用方法 | |
| IL316226A (en) | Anti-ror1 antibody and ror1-targeting engineered cells | |
| JP2023517754A (ja) | 抗ｍｕｃ１－ｓｅａ抗体 | |
| JP7496093B2 (ja) | ＣＡＲライブラリおよびｓｃＦｖの製造方法 | |
| CN119053622A (zh) | 一种抗ceacam5和ceacam6抗体及其应用 | |
| JPWO2019175885A5 (enExample) | ||
| WO2023222135A9 (en) | A method of treating solid tumor | |
| TW202400662A (zh) | 結合ｐｄ－ｌ１和ｃｌｄｎ１８．２的抗體及其用途 |